Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sentilimab Prediction Model Study in Recurrent or Metastatic Urothelial Carcinoma
ChiCTR2100047156Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in transitional cell carcinoma (TCC), sponsored by Shandong Cancer Hospital. Primary endpoint: Overall survival. Started Jul 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2100047156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047156.